Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

6 terminated/withdrawn out of 16 trials

Success Rate

53.8%

-32.7% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

2 recruiting4 with results6 terminated

Enrollment Performance

Analytics

Phase 1

11(68.8%)

Phase 2

3(18.8%)

Phase 3

2(12.5%)

16Total

Phase 1(11)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT05673057Phase 1Active Not Recruiting

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Role: lead

NCT07036380Phase 2Recruiting

MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Role: collaborator

NCT07278479Phase 1Recruiting

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Role: lead

NCT04828161Phase 2Terminated

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

Role: collaborator

NCT05098405Phase 1Terminated

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Role: lead

NCT05780463Phase 3Completed

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT04501978Phase 3Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19

Role: collaborator

NCT03418532Phase 1Terminated

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Role: lead

NCT04049903Phase 1Completed

Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors

Role: lead

NCT04870164Phase 1Terminated

Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

Role: lead

NCT03084926Phase 1Completed

First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors

Role: lead

NCT04834856Phase 2Completed

Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

Role: lead

NCT03136653Phase 1Completed

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Role: lead

NCT02194426Phase 1Completed

First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients

Role: lead

NCT01042678Phase 1Terminated

Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema

Role: collaborator

NCT01086761Phase 1Terminated

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Role: collaborator

All 16 trials loaded